Drugs / Dexborneol
Dexborneol
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07692399 | Jul 2026 → Dec 2027 expected | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05953103 | Jul 2023 → Apr 2025 | intracerebral hemorrhage | Simcere Pharmaceutical Co., Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT05035953 | Sep 2021 → Sep 2023 | ischemic stroke | Huashan Hospital | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07040085 | Aug 2025 → Jun 2027 expected | stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06674460 | Aug 2025 → Oct 2027 expected | ischemic stroke | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05885919 | Jul 2023 → Dec 2024 | ischemic stroke | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 3 | NCT05249920 | Mar 2022 → Feb 2023 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07091994 | Aug → Dec 2026 expected | ischemic stroke | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06248242 | Jun 2021 → Jun 2024 | ischemic stroke | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05836766 Comparator | Jun 2023 → Jul 2024 | cerebral artery occlusion, ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04950920 Comparator | Jun 2021 → Aug 2022 | ischemic stroke | Peking University Third Hospital | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dexborneol | “Y-6 sublingual tablets (each tablet contains 25 mg cilostazol and 6 mg dexborneol) Manufacturer: Nanjing Neurodawn Pharmaceutical Co., Ltd.” NCT05836766 ↗9“each tablet of Y-6 contained 6 mg of dexborneol and 25 mg of cilostazol; Both groups took one tablet q12h for 28 days.” NCT07040085 ↗ “Sanbexin IV 37.5 mg (edaravone 30 mg + dexborneol 7.5 mg), intravenous, twice daily, for 14 consecutive days” NCT05953103 ↗ |
| Known as | Borneol d-form | ChEMBL registry synonym — accepted as the source's own label CHEMBL486208 ↗ |
| Known as | d-borneol | “Y-2 sublingual tablets: Edaravone 30mg and d-borneol 6mg.” NCT04950920 ↗ |
| Known as | D-camphanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL486208 ↗ |
| Known as | FEMA NO. 2157, (+)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL486208 ↗ |
| Action | Inhibit | “Dexborneol is anti-inflammatory and can effectively inhibit inflammatory cytokines.” NCT06248242 ↗ |
| Modality | Small molecule | — CHEMBL486208 ↗ |
| Route | Other | “Take Y-6 sublingual tablets for 28 days continuously.” NCT05836766 ↗ |